NKE Research Update — September 17, 2026
Updated Thesis
NIKE designs, markets and distributes athletic footwear, apparel and equipment through the Nike, Jordan and Converse brands, supported by global athlete marketing, valuable intellectual property and a broad wholesale and owned-digital network. Business quality is medium: its brand moat and 22.0% ROE remain meaningful, but the moat is narrowing amid intense competition, weak direct sales and uneven product demand. Revenue declined 1.1% year over year in the most recent quarter, while earnings growth of 406.6% in the most recent quarter was materially aided by a tariff-recovery benefit rather than reflecting clean underlying momentum.
The investment grade as of this refresh is C — average business quality. Medium-tier business, attractive-tier valuation, with 9.9% upside to $39.33 fair value but an unresolved revenue and margin recovery.
Grade Change
In this research cycle, the investment grade for NIKE, Inc. moved from B to C. Medium-tier business, attractive-tier valuation, with 9.9% upside to $39.33 fair value but an unresolved revenue and margin recovery.
Key Metrics at a Glance
- Revenue growth: -1.1% year over year
- Net margin: 6.7%
- Fair value upside: +9.9% to our estimate of $39
Current price: $35.78
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. NIKE, Inc. remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full NKE research →](/stocks/NKE)